Beatrice Hahn

Prof. Beatrice Hahn

University of Pennsylvania Perelman School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1995 in Nature
Verified
Journal Article
Closed access
XWXiping Wei
Xiping Wei
SGSajal K. Ghosh
Sajal K. Ghosh
MTMaria E. Taylor
Maria E. Taylor
VJVictoria A. Johnson
Victoria A. Johnson
EEEmilio A. Emini
Emilio A. Emini
GSGeorge M. Shaw
George M. Shaw

20 March 2003 in Nature
Verified
Journal Article
Closed access
XWXiping Wei
Xiping Wei
JDJulie M. Decker
Julie M. Decker
SWShuyi Wang
Shuyi Wang
HHHuxiong Hui
Huxiong Hui
JKJohn C. Kappes
John C. Kappes
GSGeorge M. Shaw
George M. Shaw

27 May 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
BKBrandon F. Keele
Brandon F. Keele
EGElena E. Giorgi
Elena E. Giorgi
JSJesus F. Salazar-Gonzalez
Jesus F. Salazar-Gonzalez
JDJulie M. Decker
Julie M. Decker
KPKimmy T. Pham
Kimmy T. Pham
GSGeorge M. Shaw
George M. Shaw
The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 transmission and in designing effective vaccines. Here, we developed a mathematical model of random viral evolution and, together with phylogenetic tree construction, used it to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection. Viral env genes evolving from individual transmitted or founder viruses generally exhibited a Poisson distribution of mutations and star-like phylogeny, which coalesced to an inferred consensus sequence at or near the estimated time of virus transmission. Overall, 78 of 102 subjects had evidence of productive clinical infection by a single virus, and 24 others had evidence of productive clinical infection by a minimum of two to five viruses. Phenotypic analysis of transmitted or early founder Envs revealed a consistent pattern of CCR5 dependence, masking of coreceptor binding regions, and equivalent or modestly enhanced resistance to the fusion inhibitor T1249 and broadly neutralizing antibodies compared with Envs from chronically infected subjects. Low multiplicity infection and limited viral evolution preceding peak viremia suggest a finite window of potential vulnerability of HIV-1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.

4 February 1999 in Nature
Verified
Journal Article
Closed access
PDF file
FGFeng Gao
Feng Gao
EBElizabeth Bailes
Elizabeth Bailes
DRDavid L. Robertson
David L. Robertson
YCYalu Chen
Yalu Chen
CRCynthia M. Rodenburg
Cynthia M. Rodenburg
BHBeatrice Hahn
Beatrice Hahn

1 September 2011 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Closed access
PDF file
PSPaul M. Sharp
Paul M. Sharp
BHBeatrice Hahn
Beatrice Hahn
Acquired immunodeficiency syndrome (AIDS) of humans is caused by two lentiviruses, human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2). Here, we describe the origins and evolution of these viruses, and the circumstances that led to the AIDS pandemic. Both HIVs are the result of multiple cross-species transmissions of simian immunodeficiency viruses (SIVs) naturally infecting African primates. Most of these transfers resulted in viruses that spread in humans to only a limited extent. However, one transmission event, involving SIVcpz from chimpanzees in southeastern Cameroon, gave rise to HIV-1 group M—the principal cause of the AIDS pandemic. We discuss how host restriction factors have shaped the emergence of new SIV zoonoses by imposing adaptive hurdles to cross-species transmission and/or secondary spread. We also show that AIDS has likely afflicted chimpanzees long before the emergence of HIV. Tracing the genetic changes that occurred as SIVs crossed from monkeys to apes and from apes to humans provides a new framework to examine the requirements of successful host switches and to gauge future zoonotic risk.

3 April 2013 in Nature
Verified
Journal Article
Open access
PDF file
LHLiao Huaxin
Liao Huaxin
RLRebecca Lynch
Rebecca Lynch
TZTongqing Zhou
Tongqing Zhou
FGFeng Gao
Feng Gao
SAS. Munir Alam
S. Munir Alam
BHBarton F. Haynes
Barton F. Haynes
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.